Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data.

ABSTRACT:

Background

Although it is a truism that drugs benefit patients only when taken, surprisingly little is known about real-world drug-use persistence and discontinuation, even for expensive biologic drugs.

Methods

We used longitudinal self-reported drug-use data from the inflammatory bowel disease (IBD) Partners registry of people with IBD to construct Kaplan-Meier drug-use persistency graphs for biologic drug-use spans that started between 2017 and 2022.

Results

We examined 2034 drug-use spans for 1594 survey participants. Most of the biologic drugs had a 75%+ persistency rate around the one-year mark and 60%+ persistency at the 3-year mark. The overall persistency and the differences in persistency between drugs were aligned with published literature.

Conclusions

SUBMITTER: Goss Sawhney T 

PROVIDER: S-EPMC10629214 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature